WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
WuXi Biologics has launched WuXia™ RidGS, a high-yield glutamine synthetase-knockout CHO expression system platform for non-antibiotic cell line development. The platform uses zinc finger nucleases technology and achieves average clonal expression levels exceeding 6 g/L for monoclonal antibodies. The system ensures cell line stability for various therapeutic modalities, including bispecific antibodies, Fc-fusion proteins, and recombinant proteins. WuXia™ RidGS maintains stable productivity and uniform product quality without antibiotics, featuring favorable glycosylation patterns and exceptional purity profiles.
WuXi Biologics ha lanciato WuXia™ RidGS, una piattaforma espressiva basata su un sistema di cellule CHO knock-out per la sintesi della glutammina, ad alta produttività e senza uso di antibiotici. La piattaforma utilizza la tecnologia delle nucleasi a dita di zinco e raggiunge livelli medi di espressione clonale superiori a 6 g/L per anticorpi monoclonali. Il sistema garantisce stabilità delle cellule per varie modalità terapeutiche, inclusi anticorpi bispecifici, proteine Fc-fusion e proteine ricombinanti. WuXia™ RidGS mantiene una produttività stabile e una qualità del prodotto uniforme senza antibiotici, presentando modelli di glicosilazione favorevoli e profili di purezza eccezionali.
WuXi Biologics ha lanzado WuXia™ RidGS, una plataforma de sistema de expresión CHO knockout de alta productividad para el desarrollo de líneas celulares sin antibióticos. La plataforma utiliza tecnología de nucleasas de dedo de zinc y logra niveles promedio de expresión clonal superiores a 6 g/L para anticuerpos monoclonales. El sistema garantiza estabilidad de la línea celular para diversas modalidades terapéuticas, incluidas anticuerpos bispecíficos, proteínas de fusión Fc y proteínas recombinantes. WuXia™ RidGS mantiene una productividad estable y una calidad uniforme del producto sin antibióticos, presentando patrones de glicosilación favorables y perfiles de pureza excepcionales.
우시 바이오로직스(WuXi Biologics)는 WuXia™ RidGS를 출시했습니다. 이는 항생제 없이 세포주 개발을 위한 높은 수율의 글루타민합성효소 결핍 CHO 발현 시스템 플랫폼입니다. 이 플랫폼은 아연 손가락 뉴클레아제를 이용하며 평균 클론 발현 수준이 모노클로날 항체에 대해 6 g/L를 초과합니다. 이 시스템은 이중 특이 항체, Fc-융합 단백질 및 재조합 단백질을 포함한 다양한 치료 방법에 대해 세포주 안정성을 보장합니다. WuXia™ RidGS는 항생제 없이 안정적인 생산성과 균일한 제품 품질을 유지하며, 유리한 당화 패턴과 뛰어난 순도 프로파일을 특징으로 합니다.
WuXi Biologics a lancé WuXia™ RidGS, une plateforme de système d'expression CHO à haut rendement, avec élimination de la glutaminesynthétase, pour le développement de lignées cellulaires sans antibiotiques. La plateforme utilise la technologie des nucléases à doigts de zinc et atteint des niveaux d'expression clonale moyens dépassant 6 g/L pour les anticorps monoclonaux. Le système garantit la stabilité de la lignée cellulaire pour diverses modalités thérapeutiques, y compris les anticorps bispécifiques, les protéines de fusion Fc et les protéines recombinantes. WuXia™ RidGS maintient une productivité stable et une qualité de produit uniforme sans antibiotiques, affichant des modèles de glycosylation favorables et des profils de pureté exceptionnels.
WuXi Biologics hat WuXia™ RidGS eingeführt, eine Plattform für ein hochproduktivitätsfähiges CHO-Expressionssystem mit Glutaminsynthetase-Knockout zur Entwicklung von Zelllinien ohne Antibiotika. Die Plattform nutzt die Technologie der Zinkfinger-Nukleasen und erreicht durchschnittliche klonale Expressionsniveaus von über 6 g/L für monoklonale Antikörper. Das System gewährleistet die Stabilität der Zelllinie für verschiedene therapeutische Modalitäten, einschließlich bispezifischer Antikörper, Fc-Fusionsproteine und rekombinanter Proteine. WuXia™ RidGS hält eine stabile Produktivität und gleichbleibende Produktqualität ohne Antibiotika aufrecht und bietet günstige Glykosylierungsmuster sowie außergewöhnliche Reinheitprofile.
- Launch of new high-yield expression system platform WuXia™ RidGS
- High performance with clonal expression levels exceeding 6 g/L for monoclonal antibodies
- Eliminates need for antibiotics while maintaining stable productivity
- Versatile platform supporting multiple therapeutic modalities
- None.
Based on the WuXia™ platform, WuXia™ RidGS not only retains the robust cell growth, metabolism, and expression profile characteristic of WuXia™, but also boasts an average clonal expression level exceeding 6 g/L for monoclonal antibodies(mAbs). WuXia™ RidGS ensures cell line stability for mAbs, as well as for various other therapeutic modalities, including bispecific antibodies, Fc-fusion proteins, and recombinant proteins. The quality of protein products expressed by the platform showcases favorable glycosylation patterns while maintaining an exceptional purity profile. In addition, without the need for antibiotics, WuXia™ RidGS host and production cells consistently maintain stable productivity and uniform product quality throughout extensive, long-term cell line stability studies.
Dr. Chris Chen, CEO of WuXi Biologics, commented, "With the launch of WuXia™ RidGS, we are pleased to offer a more efficient alternative for the development of advanced therapeutic proteins. WuXi Biologics continues its commitment to developing tailored technology platforms that cater to the evolving needs of our global clients, accelerating the speed to market for life-saving therapies and advancing the accessibility of high-quality biologics for patients worldwide."
About the WuXia™ Cell Line Development Platform Family
WuXia™ is a proven, high-yielding (up to about 11 g/L) mammalian cell line platform developed by WuXi Biologics. Accepted by regulatory agencies worldwide, the WuXia™ platform has generated over 900 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing. WuXiaADCC Plus™ and WuXia™ RidGS mirror the impressive attributes of WuXia™, while catering to the diverse needs of global customers.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-launches-wuxia-ridgs-for-non-antibiotic-cell-line-development-302288389.html
SOURCE WuXi Biologics
FAQ
What is WuXi Biologics' new WuXia RidGS platform?
What expression levels can WuXi Biologics' WuXia RidGS achieve for monoclonal antibodies?
What therapeutic modalities can WuXi Biologics' WuXia RidGS platform support?
